Treatment of Post-Ocriplasmin Therapy Vitreolysis Induced Subretinal Fluid With Eplerenone (Mineralocorticoid Antagonists)

Exclusion Criteria

• •Patients who are pregnant, planning to become pregnant, or breastfeeding a child
• •Uncontrolled ocular hypertension or glaucoma in study (defined as IOP ≥ 25mm Hg or a cup to disc ratio (CDR) \> 0.8 despite treatment with anti-glaucoma medication)
• •Active malignancies within the last 12 months except appropriately treated carcinoma in situ of the crevices, melanoma, and prostate cancers treated with a curative intent
• •Inability to comply with study or follow-up procedures
• •Women who may become pregnant or lactating or intend to become pregnant during the study
• •Known drug allergy to ocriplasmin or eplerenone
• •Patients with known contraindications Eplerenone as outlined in the package insert